Globalagliatin Hydrochloride vs HMS1005

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: Glucokinase · full Type 2 Diabetes pipeline

Globalagliatin Hydrochloride

Developed by Eli Lilly and partners

Phase 2 in Type 2 Diabetessmall molecule
Partial signal

NCT03414892 · Phase 1 · completed

Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Reported efficacy

the mean change in glucose area under curve (AUC) from baseline. (28 days): Phase Ib, 28-day multiple ascending dose study of globalagliatin (glucokinase activator) in 24 Chinese T2DM patients (3:1 randomization, NCT03414892): high-dose globalagliatin significantly reduced FPG by LS mean -4.08 mmol/L (95% CI -5.05 to -3.12, P<0.01) vs placebo, plus significant reductions in 24-h glucose AUC and glycated albumin; mildly elevated incidences of hypoglycemia and hypertriglyceridemia; well tolerated with favorable PK. (met)

Result source: NCT03414892

HMS1005

Developed by Hua Medicine

Phase 1 in Type 2 Diabetessmall molecule
Partial signal

NCT06498284 · Phase 1 · completed

The trial randomized participants against a matched placebo with both participants and investigators blinded, but the primary measures were safety and drug levels rather than a validated diabetes outcome like HbA1c. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

The sponsor release does not cite the trial's registry number; identity rests on the matching sponsor, drug code, country, design and enrollment.

Reported efficacy

Incidence of adverse events (11 Days); Area under the plasma concentration versus time curve (AUC) (72 hour); maximum observed concentration (Cmax) (72 hours); time of the maximum observed concentration (Tmax) (72 hours); apparent terminal elimination half life (t1/2) (72 hours): US Phase Ia single ascending dose study, 40 T2D subjects: HM-002-1005 near-completely converts to HMS5552 (dorzagliatin) in vivo; prolonged half-life vs dorzagliatin; Cmax at 184.5mg single dose comparable to 75mg single dose of dorzagliatin

Result source: NCT06498284

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointGlobalagliatin HydrochlorideHMS1005
HbA1c, change—Not reported—Not reported
Body weight, change (kg)—Not reported—Not reported
HbA1c below 7%—Not reported—Not reported
Fasting plasma glucose, change—Not reported—Not reported
3-point MACE (% with event)—Not reported—Not reported

HbA1c, change

Globalagliatin Hydrochloride
—Not reported
HMS1005
—Not reported

Body weight, change (kg)

Globalagliatin Hydrochloride
—Not reported
HMS1005
—Not reported

HbA1c below 7%

Globalagliatin Hydrochloride
—Not reported
HMS1005
—Not reported

Fasting plasma glucose, change

Globalagliatin Hydrochloride
—Not reported
HMS1005
—Not reported

3-point MACE (% with event)

Globalagliatin Hydrochloride
—Not reported
HMS1005
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

HMS1005: no structured comparison results are available for Type 2 Diabetes.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Globalagliatin Hydrochloride
Phase Ib, 28-day multiple ascending dose study of globalagliatin (glucokinase activator) in 24 Chinese T2DM patients (3:1 randomization, NCT03414892): high-dose globalagliatin significantly reduced FPG by LS mean -4.08 mmol/L (95% CI -5.05 to -3.12, P<0.01) vs placebo, plus significant reductions in 24-h glucose AUC and glycated albumin; mildly elevated incidences of hypoglycemia and hypertriglyceridemia; well tolerated with favorable PK. NCT03414892 · Phase 1 · design grade: moderate · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Globalagliatin Hydrochloride's landscape · HMS1005's landscape